· Regulation · Regulation Desk
FDA removed BPC-157 from 503A and 503B compounding pharmacy formularies in 2024–2025. Timeline, current legal status by jurisdiction, and legitimate research access.
This brief is part of the Novusyn Research news desk. We track peptide clinical readouts, regulatory actions, and pharma developments in neutral, evidence-led language for scientifically literate readers.
For related context, see the full news desk, clinical trials tracker, regulation tracker, compound directory, and guides library.